Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 9/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1884866 | 0.97 | PRCP (0.44) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| Trifluoroacetic Acid SCHEMBL1884871 | 0.97 | PRCP (0.44) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL933118 | 0.93 | CYP3A4 (0.42) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL933121 | 0.93 | CYP3A4 (0.42) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL949234 | 0.92 | CYP3A4 (0.41) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL1884867 | 0.91 | PRCP (0.42) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| Trifluoroacetic Acid SCHEMBL1888959 | 0.91 | CYP3A4 (0.41) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL1882902 | 0.91 | CYP3A4 (0.44) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL1890445 | 0.90 | CYP3A4 (0.40) | PRCPCYP3A4CYP2C9KCNH2NR1I2 | |
| Trifluoroacetic Acid SCHEMBL1880874 | 0.90 | CYP3A4 (0.40) | PRCPCYP3A4CYP2C9KCNH2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| WO-2011004276-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | PRCP 211/4885CYP3A4 237/4885CYP2C9 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.